Peptide therapeutics in the management of metastatic cancers

Abstract

The arsenal of anti-cancer medicinal peptides: modes of action.

DA7R: A 7-Letter Zip Code to Target PDAC

“…1 H and 13 C nuclear magnetic resonance (NMR) spectra were recorded with a Bruker 500 Avance III operating at 500 MHz (for 1 H NMR) and 126 MHz (for 13 C NMR). Chemical shifts (δ) are given in parts per million (ppm) relative to the signal of the solvent.…”

“…Supplementary Figure S2: 1 H-NMR spectrum of 4-nitrophenyl (14-azido-3,6,9,12-tetraoxatetradecyl)carbamate (1). Supplementary Figure S3: 13 C-NMR spectrum of 4-nitrophenyl (14-azido-3,6,9,12-tetraoxatetradecyl)carbamate (1). Supplementary Figure S4: 1 H-NMR spectrum of PAPTPL-Teg-N 3 .…”

“…Using peptides is one of the possible delivery strategies to achieve tumor targeting. Peptides are extremely versatile thanks to the numerous possible combinations of natural (and also unnatural) amino acids in the sequence, and can be selected by phage display methods for their ability to recognize a desired target, such as surface proteins (over)expressed by cancer cells [ 12 , 13 , 14 ]. One may thus advantageously interfere with cellular signaling.…”

An ultra pH-responsive peptide nanocarrier for cancer gene therapy

“…The last 30 years have seen the design and synthesis of many different types of non-viral carriers made from cationic lipids, polymers, dendrimers, inorganic materials, and peptides to deliver nucleic acid to cancer cells. [10][11][12][13][14][15] Notably, peptides are low molecular weight, modifiable amino acid repeats with unique biological properties such as low toxicity, membrane permeability, cell surface targeting efficacy, and enhanced organ and tumor permeability, [16][17][18][19] providing a highly promising platform for nucleic acid drug delivery. A variety of naturally derived, synthetic or hybrid peptides with different sizes and structural features have been used for transfection of nucleic acid drugs for the treatment of cancer.…”

Repurposing the antihistamine drug bilastine as an anti-cancer metallic drug entity: synthesis and single-crystal X-ray structure analysis of metal-based bilastine and phen [Co(ii), Cu(ii) and Zn(ii)] tailored anticancer chemotherapeutic agents against resistant cancer cells

“…Most traditional anticancer chemotherapeutic agents (organic and metal-based) suffer from the challenges of severe toxicity to different organs, 10,11 inherent resistance 12,13 and poor pharmacokinetic response in vivo, 14 which result in the failure of these drug entities in R&D, clinical trials and further translation to clinical settings. Another major stake for the treatment of cancers is 'metastasis', where the cancer cells migrate to distant or neighboring tissues through blood or lymph, 15,16 resulting in secondary cancers, which are difficult to treat owing to drug resistance issues. Therefore, there is an urgent need to address these problems, which are unresolved by the present regimes of chemotherapy, including immunotherapies, and many researchers are exploring the use of innovative drug design strategies for the management of toxicity and resistance and have accomplished success to a great extent in recent times.…”